17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details
臨床試験数 : 118 / 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-014644-11-ES (EUCTR) | 22/10/2009 | 24/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P). Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de mesilato de rasagilina 1 mg en pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P). Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de mesilato de rasagilina 1 mg en pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) | Pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT 1 mg comprimidos INN or Proposed INN: RASAGILINA MESILATO Other descriptive name: RASAGILINA MESILATO | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy |